{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:44:33Z","timestamp":1794707073526,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>ATLL (Adult T-Cell Leukemia\/Lymphoma) is an aggressive hematological malignancy. This T-cell non-Hodgkin lymphoma, caused by the human T-cell leukemia virus type 1 (HTLV-1), is challenging to treat. There is no known treatment for ATLL as of yet. However, it is recommended to use Zidovudine and Interferon Alfa-based regimens (AZT\/IFN), chemotherapy, and stem cell transplant. This study aims to review the outcome of patients with different subtypes of ATLL treated with Zidovudine and Interferon Alfa-based regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search was carried out for articles evaluating outcomes of ATLL treatment by AZT\/IFN agents on human subjects from January 1, 2004, until July 1, 2022. Researchers assessed all studies regarding the topic, followed by extracting the data. A random-effects model was used in the meta-analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We obtained fifteen articles on the AZT\/IFN treatment of 1101 ATLL patients. The response rate of the AZT\/IFN regimen yielded an OR of 67% [95% CI: 0.50; 0.80], a CR of 33% [95% CI: 0.24; 0.44], and a PR of 31% [95% CI: 0.24; 0.39] among individuals who received this regimen at any point during their treatment. Our subgroup analyses\u2019 findings demonstrated that patients who received front-line and combined AZT\/IFN therapy responded better than those who received AZT\/IFN alone. It is significant to note that patients with indolent subtypes of disease had considerably higher response rates than individuals with aggressive disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IFN\/AZT combined with chemotherapy regimens is an effective treatment for ATLL patients, and its use in the early stages of the disease may result in a greater response rate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-023-02077-0","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T14:02:55Z","timestamp":1686146575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia\/lymphoma (ATLL): a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Arman","family":"Shafiee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Seighali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nooshin","family":"Taherzadeh-ghahfarokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Mardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorour","family":"Shojaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Shadabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Hasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat","family":"Haghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed-Hamidreza","family":"Mozhgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"4","key":"2077_CR1","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.3390\/cancers7040893","volume":"7","author":"JA Yared","year":"2015","unstructured":"Yared JA, Kimball AS. Optimizing management of patients with adult T cell leukemia-lymphoma. Cancers (Basel). 2015;7(4):2318\u201329.","journal-title":"Cancers (Basel)"},{"key":"2077_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-immunol-042617-053222","volume":"36","author":"CRM Bangham","year":"2018","unstructured":"Bangham CRM. Human T cell leukemia virus type 1: persistence and pathogenesis. Annu Rev Immunol. 2018;36:43\u201371.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2077_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11912-013-0332-6","volume":"15","author":"A Mar\u00e7ais","year":"2013","unstructured":"Mar\u00e7ais A, et al. Therapeutic options for adult T-cell leukemia\/lymphoma. Curr Oncol Rep. 2013;15(5):457\u201364.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"2077_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12325-018-0658-4","volume":"35","author":"O Hermine","year":"2018","unstructured":"Hermine O, Ramos JC, Tobinai K. A review of New Findings in adult T-cell Leukemia-Lymphoma: a focus on current and emerging treatment strategies. Adv Ther. 2018;35(2):135\u201352.","journal-title":"Adv Ther"},{"issue":"3","key":"2077_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3960\/jslrt.17008","volume":"57","author":"H Katsuya","year":"2017","unstructured":"Katsuya H, Ishitsuka K. Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. J Clin Exp Hematop. 2017;57(3):87\u201397.","journal-title":"J Clin Exp Hematop"},{"key":"2077_CR6","first-page":"101754","volume":"2012","author":"K Tsukasaki","year":"2012","unstructured":"Tsukasaki K, Tobinai K. Clinical trials and treatment of ATL. Leuk Res Treatment. 2012;2012:101754.","journal-title":"Leuk Res Treatment"},{"issue":"27","key":"2077_CR7","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi A, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177\u201383.","journal-title":"J Clin Oncol"},{"key":"2077_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3389\/fmicb.2020.01207","volume":"11","author":"K Tsukasaki","year":"2020","unstructured":"Tsukasaki K, et al. Diagnostic approaches and established treatments for adult t cell leukemia lymphoma. Front Microbiol. 2020;11:1207.","journal-title":"Front Microbiol"},{"issue":"1","key":"2077_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3960\/jslrt.50.9","volume":"50","author":"K Uozumi","year":"2010","unstructured":"Uozumi K. Treatment of adult T-cell leukemia. J Clin experimental hematopathology. 2010;50(1):9\u201325.","journal-title":"J Clin experimental hematopathology"},{"issue":"7","key":"2077_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","volume":"118","author":"A Bazarbachi","year":"2011","unstructured":"Bazarbachi A, et al. How I treat adult T-cell leukemia\/lymphoma. Blood. 2011;118(7):1736\u201345.","journal-title":"Blood"},{"issue":"3","key":"2077_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki K, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27(3):453\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2077_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/10428194.2021.1984455","volume":"63","author":"L Malpica","year":"2022","unstructured":"Malpica L, et al. An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia\/lymphoma. Leuk Lymphoma. 2022;63(2):315\u201325.","journal-title":"Leuk Lymphoma"},{"key":"2077_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/GO.21.00084","volume":"7","author":"L Malpica","year":"2021","unstructured":"Malpica L, et al. Real-World Data on Adult T-Cell Leukemia\/Lymphoma in Latin America: a study from the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021;7:1151\u201366.","journal-title":"JCO Glob Oncol"},{"issue":"11","key":"2077_CR14","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1007\/s00277-021-04622-9","volume":"100","author":"R Guery","year":"2021","unstructured":"Guery R, et al. Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia\/lymphoma exposed to zidovudine and interferon alfa. Ann Hematol. 2021;100(11):2813\u201324.","journal-title":"Ann Hematol"},{"key":"2077_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-142818","volume":"136","author":"DS Nogueira","year":"2020","unstructured":"Nogueira DS, et al. Adult T-Cell Leukemia\/Lymphoma: a cohort of 41 cases recorded in the brazilian T-Cell project. Blood. 2020;136:35\u20136.","journal-title":"Blood"},{"issue":"6","key":"2077_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1182\/bloodadvances.2017011106","volume":"2","author":"L Malpica","year":"2018","unstructured":"Malpica L, et al. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607\u201320.","journal-title":"Blood Adv"},{"issue":"1","key":"2077_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bjhh.2016.09.012","volume":"39","author":"PD Oliveira","year":"2017","unstructured":"Oliveira PD, et al. Adult T-cell leukemia\/lymphoma treatment in Bahia, Brazil. Revista Brasileira de Hematologia e Hemoterapia. 2017;39(1):13\u20139.","journal-title":"Revista Brasileira de Hematologia e Hemoterapia"},{"issue":"32","key":"2077_CR18","doi-asserted-by":"publisher","first-page":"51981","DOI":"10.18632\/oncotarget.10223","volume":"7","author":"M Zell","year":"2016","unstructured":"Zell M, et al. Adult T-cell leukemia\/lymphoma in the caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget. 2016;7(32):51981\u201390.","journal-title":"Oncotarget"},{"issue":"23","key":"2077_CR19","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1182\/blood.V126.23.5091.5091","volume":"126","author":"AC Cordeiro","year":"2015","unstructured":"Cordeiro AC, et al. Adult T-cell leukemia\/lymphoma: a clinical and epidemiological analysis at the Medicine School of Sao Paulo University. Blood. 2015;126(23):5091.","journal-title":"Blood"},{"key":"2077_CR20","doi-asserted-by":"crossref","unstructured":"Pimentel A et al. Clinical features and outcome of adult T-cell leukemia\/lymphoma: University of Miami experience. Retrovirology, 2014. 11.","DOI":"10.1186\/1742-4690-11-S1-O1"},{"key":"2077_CR21","doi-asserted-by":"crossref","unstructured":"Hodson A et al. Haematological and molecular responses in patients with chronic ATLL treated with zidovudine and interferon-a. Retrovirology, 2014. 11.","DOI":"10.1186\/1742-4690-11-S1-O5"},{"key":"2077_CR22","doi-asserted-by":"crossref","unstructured":"Fields P et al. Achievement of complete hematological remission and reversal of high HTLV-1 viral loads with anti CCR-4 monoclonal antibody administration in Afro caribbean patients with relapsed chronic adult T cell leukaemia (ATLL). Blood, 2014. 124(21).","DOI":"10.1182\/blood.V124.21.5474.5474"},{"key":"2077_CR23","doi-asserted-by":"crossref","unstructured":"Kchour G et al. The combination of arsenic, interferon-alpha, and zidovudine restores an \" immunocompetent-like\u201d cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology, 2013. 10(1).","DOI":"10.1186\/1742-4690-10-91"},{"issue":"35","key":"2077_CR24","doi-asserted-by":"publisher","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","volume":"29","author":"A Hodson","year":"2011","unstructured":"Hodson A, et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma. J Clin Oncol. 2011;29(35):4696\u2013701.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2077_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10428190601071717","volume":"48","author":"G Kchour","year":"2007","unstructured":"Kchour G, et al. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma. 2007;48(2):330\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2077_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/sj.thj.6200374","volume":"5","author":"O Hermine","year":"2004","unstructured":"Hermine O, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma. Hematol J. 2004;5(2):130\u20134.","journal-title":"Hematol J"},{"issue":"26","key":"2077_CR27","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJM199506293322603","volume":"332","author":"PS Gill","year":"1995","unstructured":"Gill PS, et al. Treatment of adult T-cell leukemia\u2013lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744\u20138.","journal-title":"N Engl J Med"},{"issue":"26","key":"2077_CR28","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJM199506293322604","volume":"332","author":"O Hermine","year":"1995","unstructured":"Hermine O, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332(26):1749\u201351.","journal-title":"N Engl J Med"},{"key":"2077_CR29","doi-asserted-by":"crossref","unstructured":"Tada K et al. Abacavir, an anti\u2013HIV-1 drug, targets TDP1-deficient adult T cell leukemia. Sci Adv. 1(3): p. e1400203.","DOI":"10.1126\/sciadv.1400203"},{"issue":"3","key":"2077_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1046\/j.1365-2141.1998.01068.x","volume":"103","author":"K Ishitsuka","year":"1998","unstructured":"Ishitsuka K, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T\u2010cell lines more effectively than retinoic acids. Br J Haematol. 1998;103(3):721\u20138.","journal-title":"Br J Haematol"},{"key":"2077_CR31","unstructured":"KEGG. Viral carcinogenesis - Homo sapiens (human). 2018; Available from: https:\/\/www.genome.jp\/pathway\/hsa05203+H00009."},{"issue":"8","key":"2077_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JOP.2017.021907","volume":"13","author":"N Mehta-Shah","year":"2017","unstructured":"Mehta-Shah N, Ratner L, Horwitz SM. Adult T-Cell Leukemia\/Lymphoma. J Oncol Pract. 2017;13(8):487\u201392.","journal-title":"J Oncol Pract"},{"issue":"1","key":"2077_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1742-4690-2-27","volume":"2","author":"M Matsuoka","year":"2005","unstructured":"Matsuoka M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology. 2005;2(1):27.","journal-title":"Retrovirology"},{"issue":"12","key":"2077_CR34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/jcp.2007.052456","volume":"60","author":"E Matutes","year":"2007","unstructured":"Matutes E. Adult T-cell leukaemia\/lymphoma. J Clin Pathol. 2007;60(12):1373\u20137.","journal-title":"J Clin Pathol"},{"issue":"3","key":"2077_CR35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2006-01-0067","volume":"108","author":"A Datta","year":"2006","unstructured":"Datta A, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108(3):1021\u20139.","journal-title":"Blood"},{"issue":"26","key":"2077_CR36","first-page":"6528","volume":"113","author":"G Kchour","year":"2009","unstructured":"Kchour G, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL). Blood The Journal of the American Society of Hematology. 2009;113(26):6528\u201332.","journal-title":"Blood The Journal of the American Society of Hematology"},{"issue":"3","key":"2077_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3960\/jslrt.56.135","volume":"56","author":"N Kawano","year":"2017","unstructured":"Kawano N, et al. The impact of a humanized CCR4 antibody (Mogamulizumab) on patients with aggressive-type adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation. J Clin Experimental Hematopathology. 2017;56(3):135\u201344.","journal-title":"J Clin Experimental Hematopathology"},{"issue":"5","key":"2077_CR38","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T\u2010cell leukaemia\u2010lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672\u201382.","journal-title":"Br J Haematol"},{"issue":"9","key":"2077_CR39","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.21873\/anticanres.14527","volume":"40","author":"T Jo","year":"2020","unstructured":"Jo T, et al. Mogamulizumab Plus EPOCH Therapy for patients with newly diagnosed aggressive adult T-cell Leukemia\/lymphoma. Anticancer Res. 2020;40(9):5237\u201343.","journal-title":"Anticancer Res"},{"key":"2077_CR40","unstructured":"Merck has made a business decision to discontinue all presentations of Intron A 2022; Available from: https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=724&loginreturnUrl=SSOCheckOnly."}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-023-02077-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T14:06:25Z","timestamp":1686146785000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-023-02077-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1186\/s12985-023-02077-0","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This research recieved grant from Alborz University of Medical scincves. (IR.ABZUMS.REC.1399.322) .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"118"}}